remedium bio

Remedium Bio is a gene therapy company focused on the development of treatments for a number of highly debilitating conditions. Our fundamental approach to product development utilizes proven technologies in novel ways to treat well-characterized disease pathology. To streamline R&D, we modularly apply elements of proven technology to develop local, targeted treatments focusing on clinically validated molecules and mechanistic pathways. Our lead product is a disease-modifying treatment for osteoarthritis that is based on a clinically validated mechanism. In vivo testing confirms the cartilage regenerative potential of our proprietary single-injection treatment. Our pipeline includes gene therapy treatments in the fields of Rheumatology, Endocrinology, Neurology, and Immunology.

treatment modalities

  • Rheumatology
    Osteoarthritis

    Affecting 1 in 7 adults, Osteoarthritis (OA) is the most prevalent rheumatic disorder characterized by cartilage loss and debilitating pain. As of today, there are no approved treatments capable of stopping or reversing disease progression with many patients requiring joint replacement. Remarkably, recent placebo-controlled clinical studies evaluating repeat intraarticular injection of FGF18 demonstrated the ability to regrow cartilage in arthritic knees, while potentially preventing progression to joint replacement surgery. This scientific breakthrough is limited by the need for frequent injections, with efficacy reversing upon discontinuation. Remedium is developing a novel FGF18 gene therapy, the only single-injection treatment potentially capable of reversing cartilage loss in OA.

  • Endocrinology
    Type 2 Diabetes

    Comprising roughly 90% of all Diabetes cases, and affecting nearly 500 million patients around the globe, Type 2 Diabetes (T2D) is a highly debilitating condition characterized by Beta-cell insufficiency and insulin resistance. Long term complications of T2D include heart disease, stroke, blindness, and kidney failure, with many patients requiring amputation due to inability to control the disease or manage complications. While a number of treatment options are available for T2D, the disease prevalence continues to rise and persistent reversal of disease progression is rarely achieved. Remedium is developing a novel, first-in-class, single injection gene therapy treatment potentially capable of preventing progression to daily insulin injection dependence.

  • Neurology
    Stroke

    Reaching epidemic proportions, 1 in every 4 adults will have a stroke in their lifetime, with an estimated 14 million strokes occurring each year around the world. As a classical disease of aging, the incidence rate or risk of stroke doubles each decade after the age of 45. While approved thrombolytics have demonstrated modest effects at preventing disability, there are currently no treatments capable of reliably reversing pathology beyond the level of standard rehabilitation. Recent genome-wide association studies have highlighted increased severity of post-stroke disability in patients with the several specific single-nucleotide polymorphisms, potentially resulting from reduced activity in specific cytokines. Remedium is developing a novel gene therapy treatment to potentially enhance post-stroke recovery and prevent secondary disability.

  • Immunology
    Type 1 Diabetes

    Autoimmune Diabetes or Type 1 Diabetes (T1D) is a genetic disease manifested by T-cell mediated destruction of insulin-producing Beta cells. Comprising roughly 10% of all Diabetes cases, T1D currently has no approved treatments capable of halting or reversing disease progression with nearly all patients eventually progressing to an insulin-injection dependent state. Several clinical studies have highlighted the benefit of residual C-peptide levels (persistent insulin secretion) in reducing disease severity, facilitating restoration of normoglycemia, and reducing the severity of secondary complications. Remedium is developing a novel, first-in-class gene therapy that is potentially capable of providing residual insulin supplementation to T1D patients after a single sub-cutaneous injection.

REMEDIUM PIPELINE

The Remedium Bio pipeline consists of a broad range of therapies for immune and age related conditions. The treatment modalities are founded in proven scientific fundamentals and focused on therapeutic treatments using a novel approach.

Screenshot
Background

There is so much to life

The only worthy purpose is saving it!

proven fundamentals

Remedium therapies are based on proven fundamental components including clinically validated targets, commercial delivery vectors, and time-tested manufacturing technologies.

novel approach

The technology is then applied to treating disease using a fundamentally novel, patent pending approach. An approach, uniquely matched specifically with the target condition.

Infinite Potential

Each technology serves as a potential platform, from treating conditions resulting from age related decline, to replacing extracellular proteins in a safe and adjustable way.

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!

1116 Great Plain Ave, Suite 203                        
Needham, MA                        
02492

E: info@remedium-bio.com 
P: +1 (978) 467 5217